TCM
RAPT

TimesSquare Capital Management’s RAPT Therapeutics RAPT Stock Holding History

TimesSquare Capital Management’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-63,043
Closed -$12.5M – 169
2023
Q4 		$12.5M Buy
+63,043
New +$7.8M 0.18% 135

Other funds holding RAPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

TimesSquare Capital Management's RAPT Position: Q1 2024 in Review

TimesSquare Capital Management sold out of RAPT Therapeutics (RAPT) in Q1 2024, closing a stake of 63,043 shares — an estimated $12.5M sold.

TimesSquare Capital Management first reported a position in RAPT in Q4 2023 and held it in 1 quarter. The position peaked at $12.5M in Q4 2023. 121 funds tracked by Wall St. Rank hold RAPT as of Q1 2024.

  • TimesSquare Capital Management reported no remaining RAPT Therapeutics position as of Q1 2024 after selling out during the quarter.
  • TimesSquare Capital Management sold 63,043 RAPT Therapeutics shares in Q1 2024, an estimated $12.5M.
  • TimesSquare Capital Management first reported a position in RAPT Therapeutics in Q4 2023 and held it in 1 quarter.
  • TimesSquare Capital Management's RAPT Therapeutics position peaked at $12.5M in Q4 2023.
  • 121 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2024.

Based on TimesSquare Capital Management's 13F filing for Q1 2024, filed 7 May 2024.